Publications by authors named "Shawn Estrem"

Claim this Profile
I
Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2 directed therapy, with or without abemaciclib, in ER-positive, HER2-positive advanced breast cancer: results from the phase 1a/1b EMBER study.
Manali Bhave, Komal L Jhaveri, Peter A Kaufman, Philippe Aftimos, Janine Lombard, Shawn T Estrem

Breast Cancer Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival benefit from abemaciclib in non-small cell lung cancer by Kirsten rat sarcomamutation gene expression subtype: retrospective analysis from the JUNIPER Trial.
Jiangang Liu, Hong Wang, Amit Aggarwal, Maria Jesus Ortiz-Ruiz, Elisabet Zapatero-Solana, Shawn T Estrem

Front Oncol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imlunestrant, an Oral Selective Estrogen Receptor Degrader, as Monotherapy and in Combination With Targeted Therapy in Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Phase Ia/Ib EMBER Study.
Komal L Jhaveri, Elgene Lim, Rinath Jeselsohn, Cynthia X Ma, Erika P Hamilton, Shawn T Estrem

J Clin Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Preoperative Window-of-Opportunity Study of Oral SERD, Imlunestrant, in Newly Diagnosed ER-Positive, HER2-Negative Early Breast Cancer: Results from the EMBER-2 Study.
Patrick Neven, Nicole Stahl, Maria Vidal, Miguel Martín, Peter A Kaufman, Shawn T Estrem

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imlunestrant, an oral selective estrogen receptor degrader, as monotherapy and combined with abemaciclib, in recurrent/advanced ER-positive endometrioid endometrial cancer: Results from the phase 1a/1b EMBER study.
Kan Yonemori, Valentina Boni, Kim Gun Min, Tarek M Meniawy, Janine Lombard, Shawn T Estrem

Gynecol Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.
Ernest Nadal, Mansoor Saleh, Santiago Ponce Aix, Maria Ochoa-de-Olza, Sandip Pravin Patel, Shawn T Estrem

BMC Cancer· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-In-Human Phase I Study of a Next-Generation, Oral, TGFβ Receptor 1 Inhibitor, LY3200882, in Patients with Advanced Cancer.
Timothy A Yap, Maria Vieito, Capucine Baldini, Juan Manuel Sepúlveda-Sánchez, Shunsuke Kondo, Shawn T Estrem

Clin Cancer Res· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Correction: Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, Ed Gane, Valerie Paradis, Shawn T Estrem

PLoS One· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.
Davide Melisi, Do-Youn Oh, Antoine Hollebecque, Emiliano Calvo, Anna Varghese, Shawn T Estrem

J Immunother Cancer· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Antje Wick, Annick Desjardins, Cristina Suarez, Peter Forsyth, Ivelina Gueorguieva, Shawn T Estrem

Invest New Drugs· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER.
Jonathan W Goldman, Julien Mazieres, Fabrice Barlesi, Konstantin H Dragnev, Marianna Koczywas, Shawn T Estrem

Front Oncol· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarkers and overall survival in patients with advanced hepatocellular carcinoma treated with TGF-βRI inhibitor galunisertib.
Gianluigi Giannelli, Armando Santoro, Robin K Kelley, Ed Gane, Valerie Paradis, Shawn T Estrem

PLoS One· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
TGFβ receptor inhibitor galunisertib is linked to inflammation- and remodeling-related proteins in patients with pancreatic cancer.
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque, Shawn T Estrem

Cancer Chemother Pharmacol· May 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer.
Davide Melisi, Rocio Garcia-Carbonero, Teresa Macarulla, Denis Pezet, Gael Deplanque, Shawn T Estrem

Br J Cancer· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
David Capper, Andreas von Deimling, Alba A Brandes, Antoine F Carpentier, Santosh Kesari, Shawn T Estrem

Int J Mol Sci· May 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Stephan Herbertz, J Scott Sawyer, Anja J Stauber, Ivelina Gueorguieva, Kyla E Driscoll, Shawn T Estrem

Drug Des Devel Ther· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Jordi Rodón, Michael Carducci, Juan M Sepulveda-Sánchez, Analía Azaro, Emiliano Calvo, Shawn T Estrem

Invest New Drugs· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.
Jordi Rodon, Michael A Carducci, Juan M Sepulveda-Sánchez, Analia Azaro, Emiliano Calvo, Shawn T Estrem

Clin Cancer Res· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reactivation of mitogen-activated protein kinase (MAPK) pathway by FGF receptor 3 (FGFR3)/Ras mediates resistance to vemurafenib in human B-RAF V600E mutant melanoma.
Vipin Yadav, Xiaoyi Zhang, Jiangang Liu, Shawn Estrem, Shuyu Li

J Biol Chem· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Transcriptome signature of resistance exercise adaptations: mixed muscle and fiber type specific profiles in young and old adults.
Ulrika Raue, Todd A Trappe, Shawn T Estrem, Hui-Rong Qian, Leah M Helvering

J Appl Physiol (1985)· May 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of diet-induced obese rats as an obesity model by comparative functional genomics.
Shuyu Li, Hong-Yan Zhang, Charlie C Hu, Frank Lawrence, Kelly E Gallagher, Shawn T Estrem

Obesity (Silver Spring)· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pooling samples within microarray studies: a comparative analysis of rat liver transcription response to prototypical toxicants.
Robert A Jolly, Keith M Goldstein, Tao Wei, Hong Gao, Peining Chen, Shawn T Estrem

Physiol Genomics· August 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis